Product Description: Leelamine hydrochloride is a tricyclic diterpene molecule that is extracted from the bark of pine trees[1]. Leelamine hydrochloride is a cannabinoid receptor type 1 (CB1) agonist and a inhibitor of SREBP1-regulated fatty acid/lipid synthesis in prostate cancer cells that is not affected by androgen receptor status. Leelamine hydrochloride suppresses transcriptional activity of androgen receptor, which is known to regulate fatty acid synthesis[2,3].
Applications: Metabolism-sugar/lipid metabolism
Formula: C20H32ClN
References: [1]Kuzu OF, et al. Leelamine mediates cancer cell death through inhibition of intracellular cholesterol transport. Mol Cancer Ther. 2014 Jul;13(7):1690-703./[2]A.O. Ibegbu, et al. Therapeutic Potentials and uses of Cannabinoid Agonists in Health and Disease Conditions. British Journal of Pharmacology and Toxicology 3(2): 76-88, 2012/[3]Singh KB, et al. Leelamine is a Novel Lipogenesis Inhibitor in Prostate Cancer Cells In Vitro and In Vivo. Mol Cancer Ther. 2019 Aug 8.
CAS Number: 16496-99-4
Molecular Weight: 321.93
Compound Purity: 99.06
Research Area: Cancer; Endocrinology
Solubility: DMSO : 25 mg/mL (ultrasonic;warming;heat to 60°C)
Target: Androgen Receptor;Cannabinoid Receptor;Fatty Acid Synthase (FASN)
Deutsch
English
